关注
Zachary Sethna
Zachary Sethna
在 mskcc.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
LA Rojas, Z Sethna, KC Soares, C Olcese, N Pang, E Patterson, J Lihm, ...
Nature 618 (7963), 144-150, 2023
3932023
ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity
JA Moral, J Leung, LA Rojas, J Ruan, J Zhao, Z Sethna, A Ramnarain, ...
Nature 579 (7797), 130-135, 2020
2902020
Inferring processes underlying B-cell repertoire diversity
Y Elhanati, Z Sethna, Q Marcou, CG Callan Jr, T Mora, AM Walczak
Philosophical Transactions of the Royal Society B: Biological Sciences 370 …, 2015
2152015
OLGA: fast computation of generation probabilities of B-and T-cell receptor amino acid sequences and motifs
Z Sethna, Y Elhanati, CG Callan Jr, AM Walczak, T Mora
Bioinformatics 35 (17), 2974-2981, 2019
1842019
Predicting the spectrum of TCR repertoire sharing with a data‐driven model of recombination
Y Elhanati, Z Sethna, CG Callan Jr, T Mora, AM Walczak
Immunological reviews 284 (1), 167-179, 2018
1262018
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
M Łuksza, ZM Sethna, LA Rojas, J Lihm, B Bravi, Y Elhanati, K Soares, ...
Nature 606 (7913), 389-395, 2022
1172022
Population variability in the generation and selection of T-cell repertoires
Z Sethna, G Isacchini, T Dupic, T Mora, AM Walczak, Y Elhanati
PLOS Computational Biology 16 (12), e1008394, 2020
532020
Insights into immune system development and function from mouse T-cell repertoires
Z Sethna, Y Elhanati, CR Dudgeon, CG Callan Jr, AJ Levine, T Mora, ...
Proceedings of the National Academy of Sciences 114 (9), 2253-2258, 2017
412017
Fundamental immune–oncogenicity trade-offs define driver mutation fitness
D Hoyos, R Zappasodi, I Schulze, Z Sethna, KC de Andrade, DF Bajorin, ...
Nature 606 (7912), 172-179, 2022
392022
Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.
VP Balachandran, LA Rojas, Z Sethna, K Soares, E Derhovanessian, ...
Journal of Clinical Oncology 40 (16_suppl), 2516-2516, 2022
262022
Accelerating multidimensional NMR and MRI experiments using iterated maps
MA Frey, ZM Sethna, GA Manley, S Sengupta, KW Zilm, JP Loria, ...
Journal of Magnetic Resonance 237, 100-109, 2013
132013
Generative models of T-cell receptor sequences
G Isacchini, Z Sethna, Y Elhanati, A Nourmohammad, AM Walczak, ...
Physical Review E 101 (6), 062414, 2020
102020
GeneVector: Identification of transcriptional programs using dense vector representations defined by mutual information
N Ceglia, Z Sethna, F Uhlitz, V Bojilova, N Rusk, B Burman, A Chow, ...
bioRxiv, 2022.04. 22.487554, 2022
62022
RNA vaccines for cancer: Principles to practice
P Guasp, C Reiche, Z Sethna, VP Balachandran
Cancer Cell, 2024
12024
Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector
N Ceglia, Z Sethna, SS Freeman, F Uhlitz, V Bojilova, N Rusk, B Burman, ...
Nature Communications 14 (1), 4400, 2023
12023
Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness
D Hoyos, R Zappasodi, I Schulze, Z Sethna, KC de Andrade, DF Bajorin, ...
Nature 606 (7914), E5, 2022
12022
824 High quality neoantigens are immunoedited in long-term pancreatic cancer survivors
Z Sethna, M Luksza, L Rojas, K Soares, J Leung, J Lihm, D Hoyos, ...
Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021
12021
Characterizing the T cell response to a personalized cancer vaccine
Z Sethna
Bulletin of the American Physical Society, 2024
2024
TCRi: Information theoretic metrics for single cell RNA and TCR sequencing in cancer
N Ceglia, ZM Sethna, Y Elhanati, B Burman, A Chow, D Zamarin, ...
bioRxiv, 2022.10. 01.510457, 2022
2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitness (vol 606, pg 172, 2022)
D Hoyos, R Zappasodi, I Schulze, Z Sethna, KC de Andrade, DF Bajorin, ...
Nature, 2022
2022
系统目前无法执行此操作,请稍后再试。
文章 1–20